plerixafor
plerixafor: 9 clinical trials tracked.
plerixafor evidence translation
What we can confirm
9 tracked trials
What it means
What to watch
Prepared research question
What is verified about plerixafor, and what remains unknown?
Traceable citations · Unknowns marked
See linked entities and source evidence6 indications · 3 study sponsors
Clinical Trials (9)
Phase 1/2 Base-Edited Hematopoietic Stem/Progenitor Cell X-Linked Severe Combined Immunodeficiency Gene Therapy
Primary endpoint: Quantify frequency and severity of adverse events (AEs) related to study agent from infusion to 12 months after infusion.
Pre-transplant Purging and Post-transplant MRD-guided Maintenance Therapy With Elranatamab in Patients With High-risk Multiple Myeloma
Primary endpoint: Safety and adverse events (AEs)
A Phase I/II Pilot Study of Memory-like NK Cells to Consolidate TCRαβ T Cell Depleted Haploidentical Transplant in High-risk AML
Primary endpoint: Safety of patients being administered donor-derived ML NK cells following TCR alpha beta depleted haploidentical cell transplant
Phase 1/2 Trial of Base Editing for Mutation Repair in Hematopoietic Stem & Progenitor Cells for X-linked Chronic Granulomatous Disease
Primary endpoint: To evaluate the safety of base-edited autologous CD34+ cells
A Phase 1/2, Open-Label, Multicenter, Single-Arm Study to Assess the Safety, Tolerability, and Efficacy of BIVV003 for Autologous Hematopoietic Stem Cell Transplantation in Patients With Severe Sickle Cell Disease
Primary endpoint: Percentage of Participants who are Alive at Post-transplantation Day 100
A Follow-Up Study to Add Whole Brain Radiotherapy (WBRT) to Standard Temozolomide Chemo-Radiotherapy in Newly Diagnosed Glioblastoma (GBM) Treated With 4 Weeks of Continuous Infusion Plerixafor
Primary endpoint: Proportion of Progression Free Survival Participants (PFS) at Six Months
A Multi-center Randomized Phase II Study of the Impact of CD34+ Cell Dose on Absolute Lymphocyte Count Following High-Dose Therapy and Autologous Stem Cell Transplantation for Relapsed and Refractory Diffuse Large B-cell Lymphoma (DLBCL)
Primary endpoint: progression-free survival (PFS)
Hematopoietic Stem Cell Mobilization in Idiopathic CD4 Lymphocytopenia Patients and Healthy Controls for the Study of T Cell Maturation and Trafficking in Murine Models
Primary endpoint: To mobilize CD34+ HPCs in ICL patients and healthy volunteers for collection and transfer into immunocompromised mice to investigate thymic development, survival, and trafficking of these cells in murine lymphoid and non-lymphoid organs
Phase I/II Study of Cellular Immunotherapy Using Central Memory-Enriched CD8+ T Cells Lentivirally Transduced to Express A CD19-Specific Chimeric Immunoreceptor Following Peripheral Blood Stem Cell Transplantation for Patients With High-Risk Intermediate Grade B-Lineage Non-Hodgkin Lymphoma
Primary endpoint: Number of Participants With Dose Limiting Toxicities (DLTs)